Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2001, p. 3503-3513, Vol. 21, No. 10
Department of Chemistry and Biochemistry,
University of Colorado at Boulder, Boulder, Colorado 80309-0215
Received 6 October 2000/Returned for modification 3 December
2000/Accepted 20 February 2001
NFATp is one member of a family of transcriptional activators that
regulate the expression of cytokine genes. To study mechanisms of NFATp
transcriptional activation, we established a reconstituted transcription system consisting of human components that is responsive to activation by full-length NFATp. The TATA-associated factor (TAFII) subunits of the TFIID complex were required for
NFATp-mediated activation in this transcription system, since
TATA-binding protein (TBP) alone was insufficient in supporting
activated transcription. In vitro interaction assays revealed that
human TAFII130 (hTAFII130) and its
Drosophila melanogaster homolog dTAFII110 bound
specifically and reproducibly to immobilized NFATp. Sequences contained
in the C-terminal domain of NFATp (amino acids 688 to 921) were
necessary and sufficient for hTAFII130 binding. A partial
TFIID complex assembled from recombinant hTBP, hTAFII250,
and hTAFII130 supported NFATp-activated transcription,
demonstrating the ability of hTAFII130 to serve as a
coactivator for NFATp in vitro. Overexpression of hTAFII130
in Cos-1 cells inhibited NFATp activation of a luciferase reporter.
These studies demonstrate that hTAFII130 is a coactivator for NFATp and represent the first biochemical characterization of the
mechanism of transcriptional activation by the NFAT family of activators.
Transcription is a highly regulated
process of RNA synthesis, the initiation of which is a primary control
point in gene expression. In eukaryotes, genes encoding mRNA are
transcribed by RNA polymerase II, a multiprotein enzyme. Reconstitution
of an in vitro transcription system with purified RNA polymerase II
proved to be insufficient for RNA synthesis from promoters, propelling
the identification of a phylogenetically conserved set of general
transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH)
that are necessary for basal transcription (reviewed in reference
45). The assembly of RNA polymerase II and the general
transcription factors on promoter DNA leads to the formation of stable
nucleoprotein complexes (preinitiation complexes) that are
transcriptionally competent in vitro. Preinitiation complex formation
can be regulated by the action of activators and repressors. The
activities of these distinct regulatory proteins can promote
(activators) or repress (repressors) the recruitment of general
transcription factors and RNA polymerase II onto promoters, resulting
in promoter-specific augmentation or suppression of transcription.
Eukaryotic organisms have evolved elaborate mechanisms for the
deployment of RNA polymerase II onto specialized promoter elements that
can modulate basal promoter strength. Many RNA polymerase II promoters
contain one or more of three identified core promoter elements that
direct accurate transcription initiation (5): the TATA
box, the initiator element, and the downstream promoter element. In a
temporal scheme, TFIID is the first basal factor to bind to a core
promoter, serving as a nucleation center for the rest of the
transcriptional apparatus (60). The architecture of TFIID
is also phylogenetically conserved, and it appears that TFIID complexes
in yeast, Drosophila melanogaster, and humans have a similar
complement of subunits (6). TFIID is a sequence-specific DNA binding general transcription factor consisting of TATA-binding protein (TBP) and 10 to 13 TATA-associated factors (TAFIIs)
that together can recognize the TATA box, initiator, and downstream promoter elements.
The orchestration of transcriptional activation at mammalian promoters
is a dynamic process that involves the recruitment of functional
protein complexes in a highly regulated manner. Activators can exert
their effects by interacting with components of the transcription
machinery, including subunits of the TFIID and mediator complexes
(19, 35), as well as by recruiting chromatin-modifying
complexes (63). In general, it is the activation domains
of activators that bind specific components of the transcriptional apparatus. Activation domains display target specificity depending on
their amino acid composition and have been categorized as rich in a
particular type of amino acid, for example, acidic residues, glutamines, or prolines (58).
A limiting step in the process of preinitiation complex formation at
some promoters in vitro is the recruitment of TFIID, which is a common
target of many eukaryotic activators (19). TFIID binding
to promoters is a central event in transcription initiation, regardless
of the manner by which the basal transcriptional components are
assembled, either following a step-wise assembly or through the
recruitment of a holoenzyme (7). In some cases, upstream
activators that interact with TFIID components achieve efficient
recruitment of TFIID (28, 54, 62). Although direct interactions between TBP and activators have been noted, the primary target within TFIID is not TBP but the TAF subunits of the TFIID complex. TAFIIs were coined coactivators in recognition of
their requirement for activated transcription in in vitro systems
(12, 48). The validity of the coactivator function of TAFs
has been firmly established from examples in yeast,
Drosophila, and human systems (1). Recently,
the ability of TAFIIs to adopt multifunctional roles as
components of functionally distinct complexes, including TFIID, SAGA,
PCAF, and TFTC, has been demonstrated.
Although TAFs can function as coactivators, other mechanisms of
transcriptional activation exist. The mediator complex, which was first
identified in yeast and more recently in humans, is also a target of
transcriptional activators and serves to coactivate transcription
(35). In the context of chromatin, nucleosome remodeling
complexes and histone acetyltransferases, such as CREB-binding protein
(CBP), function to coactivate transcription (63). It is
likely that activators can stimulate transcription by many different
mechanisms depending upon the conditions and the context of the
promoter at which the activator binds.
The nuclear factor of activated T cells (NFAT) family is a family
of activators that exert a pivotal effect on the transcriptional regulation of genes encoding immunomodulatory cytokines
(reviewed in reference 50). NFATp (NFAT1 or NFATc2) is one
member of the NFAT family (39), which also includes NFATc
(NFAT2 or NFATc1), NFAT3 (NFATc4), NFAT4 (NFATc3 or NFATx), and NFAT5
(21, 37, 43). NFATp, NFATc, and NFAT4, which are activated
during immune responses, participate in the activation of T cells
(34, 50). A regulated burst of NFATc activity appears to
be critical for proper cardiac muscle cell differentiation during
embryogenesis (49). NFAT3 functions in cardiac hypertrophy
(42). NFAT4 has been implicated in intrathymic development
of immature thymocytes (37). NFAT5, also known as TonEBP,
is involved in the transcriptional regulation of osmotic stress
response genes (30, 41).
All NFAT proteins are DNA binding proteins whose DNA binding domains
are conserved between family members and phylogenetically within
mammalian systems (20, 21, 23, 30, 37). The DNA binding
domains of NFAT proteins, with the exception of NFAT5, are sufficient
for cooperative DNA binding in association with Fos-Jun heterodimers
(21, 24, 30), and an X-ray structure revealed contacts
between the DNA binding domain of NFAT and the basic leucine zipper
domains of c-Fos and c-Jun (9). In contrast to the
well-characterized DNA binding properties of NFAT proteins, less is
known of the transactivation properties that are conferred by their
activation domains. In the case of NFATp, two activation domains have
been mapped to the N- and C-terminal regions flanking the central DNA
binding domain using transient transfection assays and in vitro
transcription experiments (25, 32). The N-terminal region
of NFATp has been shown to interact with p300 and CBP and is proposed
to play a role in transcriptional activation by NFATp in T cells
(17). In general, the C-terminal regions of NFAT proteins
exhibit great sequence variation, suggesting the possibility for
functional differences between NFAT proteins.
NFAT transcriptional activity is regulated by cycles of
dephosphorylation and phosphorylation involving the phosphatase
calcineurin and a number of kinases (2, 3, 10, 11, 24, 29, 31, 36, 44, 47, 59, 65). A conserved regulatory domain located N
terminal to the DNA binding domain of NFAT proteins has been shown to
confer calcineurin-mediated nuclear localization (2, 33,
36). NFAT proteins exist as phosphoproteins in various tissues,
but their activation in T cells has been investigated most thoroughly.
Typically, antigen-stimulated T cells respond by activating a
calcium-dependent signaling pathway that promotes the activation of
calcineurin (11). Activated calcineurin dephosphorylates NFAT proteins, which triggers the accumulation of NFAT proteins in
nuclei (24, 43, 55). Treatment of cells with both a
calcium ionophore and a phorbol ester mimics conditions conducive for NFAT nuclear accumulation and NFAT-activated transcription
(14).
We discovered and characterized one mechanism by which NFATp activates
transcription. Using a combination of protein-protein interaction
assays, in vitro transcription experiments, and transient transfection
assays we identified a target of NFATp in the general transcription
machinery and investigated its role in mediating NFATp activation in
vitro and in cells. Our results support a model in which the unique
C-terminal region of NFATp binds the TAFII130 subunit of
human TFIID to activate transcription.
Plasmids and baculoviruses.
Plasmid pREP-NFATp was provided
by Tim Hoey (Tularik, Inc.) (21). Plasmids
pBS-KS+-NFATp, pVL1392-HAX-NFATp,
pBS-KS+-NFATp(NdeI), and pVL-GST-NFATp have been described
previously (25). pBS-NFATp(1-686) and pBS-NFATp(391-921)
were generated using single-stranded pBS-KS+-NFATp(NdeI)
for site-directed mutagenesis. In the case of pBS-NFATp(1-686) a stop
codon was created in the NFATp cDNA after amino acid (aa) 686 using an
oligonucleotide of sequence
5'-GACGGAGCCCACGTAAGAATTCGACCCCACTCTG-3'. In the case of
pBS-NFATp(391-921) a unique in-frame ATG codon contained in an
NdeI site was created in place of the codon for aa 390 using
an oligonucleotide of sequence
5'-CATCTGCAGCATCCATATGACTGCATCCCTC-3'. pT
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.10.3503-3513.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human TAFII130 Is a Coactivator
for NFATp

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-NFATp(1-686)
and pT
-NFATp(391-921) were generated by subcloning NdeI-EcoRI fragments from pBS-NFATp(1-686) and
pBS-NFATp(391-921), respectively, into plasmid pT
-STOP (gift of R. Tjian) digested with NdeI and EcoRI.
pGEX-NFATp(688-921) was created by using pBS-KS+-NFATp(NdeI) as template DNA in Vent-catalyzed
(Promega) PCRs using primers PNF688-NdeI
(5'-ATCTGGAATTCCATATGGAATATGACCCCACTCTG-3') and PNF921-EcoRI
(5'-ATCTGGAATTCCTCGGATCAAAGATCACAG-3'). This generated a DNA
fragment that was digested with NdeI and EcoRI and subsequently ligated with NdeI- and EcoRI-cut
pGEX-2TKN (gift of S. Ruppert and R. Tjian). Plasmids used for
expression of TAFs have been described previously:
pT
-hTAFII250 (52),
pT
-dTAFII30
(64),
pT
-dTAFII30
(64),
pT
-dTAFII110 (22), and
pT
-dTAFII150 (61) were provided by R. Tjian and pT
-hTAFII130,
pT
-hTAFII100, and pCMV-hTAFII130 were
provide by N. Tanese (56).
82 to
64 of
the murine IL-4 promoter) upstream of the adenovirus major late core
promoter (
53 to +10) and a 200-bp G-less cassette. To create
pNFAT3-MLP-G-less a DNA fragment containing the three NFAT
sites was recovered after digestion of pNFAT3-E1B-CAT
(25) with XbaI and was ligated into the
XbaI site of p
ML200 (gift of J. Parvin) (4,
46). The reporter plasmid pGL3-NFAT3-Luciferase was
created by engineering KpnI and SacI sites into
the ends of a PCR fragment bearing three NFAT sites from
pNFAT3-E1B-CAT. The PCR product was digested with
KpnI and SacI and ligated into the pGL3-basic
luciferase reporter construct (Promega).
Expression and purification of recombinant NFATp proteins.
Recombinant hemagglutinin (HA)-NFATp was purified as previously
described (25). For the preparation of HA-NFATp, Hi-five cells were infected with the HA-NFATp virus for 44 h at 27°C. Cells were harvested by low-speed centrifugation and resuspended in
lysis buffer (20 mM Tris [pH 7.9], 20% [vol/vol] glycerol, 1 mM
EDTA, 0.5 M NaCl, 0.1% NP-40, 0.2 mM phenylmethylsulfonyl fluoride
[PMSF], 1 µg of leupeptin/ml, 1.4 µg of pepstatin A/ml, and 1 mM
dithiothreitol [DTT]). Sonication was performed at 4°C for 5 min
before centrifugation at 16,000 × g for 20 to 30 min. The recombinant protein was purified on anti-HA-conjugated beads and
washed two times in TGEMD buffer (20 mM Tris [pH 7.9], 20% [vol/vol] glycerol, 1 mM EDTA, 5 mM MgCl2, 0.1% NP-40,
0.2 mM PMSF, 1 µg of leupeptin/ml, 1.4 µg of pepstatin A/ml, and 1 mM DTT) containing 1 M NaCl and an additional two times in TGEMD buffer
containing 0.2 M NaCl. HA-NFATp was subsequently eluted with 1 mg of HA
peptide/ml in elution buffer (20 mM Tris [pH 7.9], 20% [vol/vol]
glycerol, 1 mM EDTA, 5 mM MgCl2, 0.2 M NaCl, 0.1% NP-40,
0.2 mM PMSF, 1 µg of leupeptin/ml, 1.4 µg of pepstatin A/ml, and 1 mM DTT). The eluate was spun through a Millex-GV4 filter, frozen in
liquid nitrogen, and stored at
80°C. Glutathione S-transferase (GST) NFATp (in Hi-five cells),
FLAG-hTAFII130 (in Sf-9 cells), FLAG-hTAFII100
(in Sf-9 cells), and HA-hTAFII250 (in Sf-9 cells) were
expressed in the indicated cells using a similar protocol, with the
exception that cell lysates were aliquoted and frozen prior to
purification on the appropriate affinity resin (see below).
-D-galactoside at a 0.6 mM
final concentration. After 2 h, cells were harvested and the cell
pellet was resuspended in a buffer containing 20 mM Tris (pH 7.9), 20%
(vol/vol) glycerol, 1 mM EDTA, 100 mM NaCl, 1 mM DTT, and 0.2 mM PMSF
and sonicated with four 20-s pulses. After centrifugation, the
supernatant was aliquoted, frozen in liquid nitrogen, and stored at
80°C.
Protein-protein interaction assays. GST fusion proteins and GST were immobilized by incubating cell extracts with glutathione-Sepharose beads for 2 h at 4°C. Immobilized proteins were washed two times in 10-bead volumes of TGEMD buffer containing 1 M NaCl [TGEMD (1 M NaCl)] followed by two washes in 10-bead volumes of TGEMD buffer containing 0.1 M NaCl [TGEMD (0.1 M NaCl)]. Prior to use in interaction assays, the amount of each protein on the beads was estimated and approximately 0.5 µg of total immobilized protein was added to each interaction assay. Input proteins either were made in a rabbit reticulocyte transcription-translation system (TNT; Promega) in the presence of [35S]methionine, were provided by insect cell lysates containing FLAG-hTAFII130 (see Fig. 3C), or consisted of purified TFIID and TBP (see Fig. 3D). Immobilized proteins and extracts containing target (input) proteins were incubated with micrococcal nuclease at 30°C for 10 min. Input proteins were added to the immobilized GST fusion proteins and nutated for 2 h at 4°C. After washing four times with 10-bead volumes of TGEMD (0.1 M NaCl), the bound fraction was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography (or phosphorimagery), silver staining, or immunoblotting (as indicated in the figure legends). Similar conditions were used for interaction assays with immunoprecipitated FLAG-hTAFII130 and NFATp, except that the FLAG-hTAFII130 was purified on M2 affinity beads (Sigma).
Assembly of partial TFIID complexes.
Partial TFIID
complexes, hTBP-hTAFII250-hTAFII130 and
hTBP-hTAFII250hTAFII100, were assembled in
multiple steps (see Fig. 4A). In summary, the
HA-TAFII250-hTBP complex was preassembled and eluted prior
to its addition to the second binding reaction with immobilized
FLAG-hTAFII130 or FLAG-hTAFII100. First,
HA-hTAFII250 was purified from an Sf-9 extract by nutation
with anti-HA antibody immobilized on protein A-Sepharose 4 Fast Flow
(Amersham Pharmacia) for 6 h at 4°C. Immobilized
HA-hTAFII250 was washed extensively with TGEMD (1 M NaCl)
followed by TGEMD (0.2 M NaCl). Second, a partially purified fraction
of human TBP (hTBP) (expressed in E. coli) was added to the
immobilized HA-hTAFII250 and nutated overnight at 4°C.
Third, FLAG-hTAFII130 and FLAG-hTAFII100 were purified from insect cell extracts by nutation with anti-FLAG M2
affinity beads for 4 h at 4°C. Non-specifically bound proteins were removed by a series of washes in TGEMD (1.0 M NaCl), followed by
TGEMD (0.1 M NaCl). Fourth, after washing in TGEMD (0.2 M NaCl) the
HA-TAFII250-TBP complex was eluted in a 2-h nutation with 1 µg of HA peptide/µl that was resuspended in elution buffer (20 mM
Tris [pH 7.9], 20% glycerol, 1 mM EDTA, 5 mM MgCl2, 0.2 M NaCl, 0.1% NP-40, 2 mM PMSF, 1 mM DTT, 1 µg of leupeptin/ml, 1.4 µg of pepstatin A/ml). Fifth, the eluted HA-TAFII250-TBP
complex was added to immobilized FLAG-hTAFII130 and
FLAG-hTAFII100 and nutated for 6 h at 4°C. Sixth,
the beads were washed four times in TGEMD (0.1 M NaCl). Finally, FLAG
peptide (Sigma) was used at a final concentration of 0.5 mg/ml in
elution buffer to elute the complexes during a 2-h nutation at 4°C.
The eluted fractions were spun through a Millex-GV4 filter, frozen in
liquid nitrogen, and stored at
80°C.
In vitro transcription. Transcription reactions using the reconstituted transcription system were performed as previously described (16), with the following modifications. Each reaction contained 50 ng of NFAT3-MLP-G-less template. Where indicated, HA-NFATp (50 ng) was preincubated with promoter DNA for 5 min at 30°C. TFIID, TBP, or partial TFIID complexes were added to reactions at equivalent final molar concentrations (as determined by anti-TBP immunoblotting; 16) and incubated for 15 min at 30°C prior to the addition of the remaining general transcription factors (TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH) and RNA polymerase II. After the addition of the general transcription factors, reactions were incubated at 30°C for 20 min. Nucleoside triphosphates were added and RNA synthesis was allowed to proceed for 20 min at 30°C. Transcription reactions were stopped with 100 µl of a solution containing 3.1 M ammonium acetate, 10 µg of carrier yeast RNA, and 15 µg of proteinase K. After ethanol precipitation, the samples were resolved by 6% denaturing PAGE and analyzed with a PhosphorImager.
Transfection assays. Cos-1 cells were transfected with Lipofectamine reagent (GIBCO) for 6 h at 37°C using 1.3 µg of total DNA and 3.2 µl of Lipofectamine. Transfections consisted of the following quantities of DNA (see legend to Fig. 5 for amounts used in specific experiments): 50 to 500 ng of pREP4-RSV-NFATp or the parental vector, 100 ng of pCMV-hTAFII130 or the pCMV parental vector, 1 µg of pGL-NFAT3-Luc, and 100 ng of pRL-TK-Renilla luciferase reporter. Where indicated, cells were stimulated with 1 µM ionomycin (Calbiochem) and 20 µg of phorbol-12-myristate-13-acetate (PMA)/ml for various times at 37°C prior to harvest. Cell lysates were prepared by sonication for 5 min at 4°C in 1× lysis buffer (Promega). The dual luciferase reporter assay system (Promega), which includes the analysis of firefly luciferase and Renilla luciferase within a single sample, was used for the quantification of reporter gene expression. Luciferase activities were determined using an EG&G Berthold's Microlumat LB96P luminometer. NFAT-driven firefly luciferase activity was normalized by dividing firefly luciferase units by the units corresponding to Renilla luciferase activity.
| |
RESULTS |
|---|
|
|
|---|
To study mechanisms of transcriptional activation by human NFATp
we developed a protocol for the expression and purification of
recombinant human NFATp containing an N-terminal HA tag in insect cells
using a recombinant baculovirus (25). HA-NFATp was
purified from insect cell lysates using anti-HA affinity chromatography followed by elution with an epitope peptide. The purification resulted
in a nearly homogenous preparation of HA-NFATp (Fig. 1A). The recombinant protein was
functional in DNA binding on its own as well as in cooperation with
AP-1 proteins, as assessed by DNase I footprinting (25).
|
TFIID TAFs function as coactivators for NFATp transcriptional activation in a reconstituted transcription system. Analysis of the transcriptional properties unique to NFATp required the creation of an NFAT-responsive promoter for in vitro transcription studies and the development of a human reconstituted transcription system that is responsive to NFATp. In designing an NFATp-responsive DNA template, we positioned three high-affinity NFAT-binding sites upstream of the adenovirus major late core promoter and a 200-bp G-less cassette. For in vitro transcription studies we utilized a system consisting of purified recombinant and native human general transcription factors, including recombinant TFIIA (rTFIIA), rTFIIB, rTFIIE, rTFIIF, native TFIIH (nTFIIH), nRNA polymerase II, and either nTFIID or rTBP. We previously showed that this transcription system is responsive to recombinant NFATp, that NFATp activation using the reporter template is not dependent on AP-1 proteins, and that AP-1 proteins do not contaminate the purified transcription system (25). The reconstituted transcription system provided us with a tool to study mechanisms of transcriptional activation by NFATp in the absence of AP-1 proteins and allowed us to investigate the roles of TFIID TAFs in NFATp activation.
HA-NFATp activated transcription an average of sevenfold above the basal level in the reconstituted transcription system containing holo-TFIID (Fig. 1B, compare lanes 3 and 4). Reactions reconstituted with TBP in place of TFIID showed at most a 50% increase over basal transcription (Fig. 1B, lanes 1 and 2) and on average a 20% increase over basal transcription (i.e., 1.2-fold activation). Hence, the TAF subunits of TFIID were required for high levels of transcriptional activation by HA-NFATp. In this transcription system we observe a higher level of basal transcription when using TBP in place of TFIID even though equivalent molar concentrations of TBP and TFIID were used (16). This is likely to be due to domains present in the TFIID complex that inhibit its binding to DNA, such as the N terminus of TAFII250 (27). Titration of TBP to lower levels did not allow a higher level of transcriptional activation by NFATp (data not shown). Control reactions that lacked either TBP or TFIID but were complemented with the activator and all other components of the basal transcription machinery showed no detectable RNA synthesis (data not shown; see Fig. 4D), indicating that the transcription system is absolutely dependent on an external source of TBP or TFIID. Consistent with current models of transcriptional activation by many mammalian activators, our experiments demonstrate that transcriptional activation by NFATp can be mediated by the TAF subunits of TFIID in vitro.NFATp binds hTAFII130 and dTAFII110.
It has previously been observed that activation domains display binding
specificity toward distinct TAF subunits of the TFIID complex
(19). We tested NFATp for the ability to interact with TAFs using in vitro protein-protein interaction assays. To perform the
interaction assays, we expressed NFATp as a GST fusion protein in
insect cells using a recombinant baculovirus. Purified GST-NFATp bound
DNA and activated transcription in vitro (25). As a
convenient source of TAFs for the initial round of interaction assays
we expressed a variety of Drosophila and human TAFs using in
vitro transcription and translation in rabbit reticulocyte lysate.
GST-NFATp was immobilized on glutathione-Sepharose beads, mixed with
input TAF proteins for several hours, and washed extensively, and bound protein was analyzed by SDS-PAGE and autoradiography. GST-NFATp interacted specifically with Drosophila TAFII110
(dTAFII110) but not with dTAFII30
,
dTAFII30
, dTAFII150, or human
TAFII250 (hTAFII250) (Fig.
2A). In all cases, control GST protein
that was immobilized failed to interact with input proteins or
interacted less well than immobilized GST-NFATp. To further
examine the interaction between GST-NFATp and TAFs we obtained
expression vectors for two other human TAFs, hTAFII130 (the
homolog of dTAFII110) and hTAFII100 (the
homolog of dTAFII80). As shown in Fig. 2B, GST-NFATp interacted with hTAFII130 but not with
hTAFII100. As an additional test of the interaction
between NFATp and hTAFII130 we immobilized FLAG-hTAFII130 that was expressed in insect cells on M2
affinity beads. The immobilized FLAG-hTAFII130 was
incubated with HA-NFATp (purified from insect cell lysates). After
extensive washing, bound protein was resolved by SDS-PAGE and analyzed
by silver staining. As shown in Fig. 2C, NFATp bound immobilized
hTAFII130. Together these results demonstrate that the
human and Drosophila homologs of a subunit of TFIID interact
with NFATp.
|
The C-terminal transactivation domain of NFATp is necessary and
sufficient for hTAFII130 interaction.
To identify the
region of NFATp that interacts with hTAFII130, in vitro
protein-protein interaction assays were conducted using deletion
mutants representing N- and C-terminal truncations of NFATp.
NFATp(1-686) contains the N-terminal transactivation domain, the
calcineurin binding domain, and the DNA binding domain (Fig.
3A). NFATp(391-921)
contains the DNA binding domain and the C-terminal transactivation
domain. Along with the full-length version of NFATp, these deletion
mutants were in vitro translated in the presence of
[35S]methionine. FLAG-hTAFII130 expressed in
insect cells was immobilized on M2 affinity beads, in parallel with
control M2 beads that were exposed to an insect cell extract lacking
expressed FLAG-hTAFII130. Full-length and truncated NFATp
were added to these beads, and after sufficient mixing, reactions were
subjected to a series of washes before analysis by SDS-PAGE and
autoradiography (Fig. 3B). Full-length NFATp and NFATp(391-921)
bound to immobilized FLAG-hTAFII130. In contrast,
NFATp(1-686) did not interact with hTAFII130. Binding
was dependent on the presence of hTAFII130, since
control beads that were not exposed to recombinant
hTAFII130 failed to bind NFATp. Our results show that
the C-terminal region of NFATp (aa 687 to 921) is required for
interaction with hTAFII130.
|
TAFII130 is a coactivator for NFATp in vitro.
Native mammalian TFIID consists of 10 to 13 TAFs and TBP, whose
internal interactions among the subunits have been defined by the
efforts of many investigators. In vitro assembly of partial TFIID
complexes from recombinant TBP and TAF subunits has previously been
accomplished (8). In fact, the assembly of partial TFIID complexes and their analysis in reconstituted transcription systems has
been used as a direct approach for demonstrating the function of
individual TAFs as coactivators (8, 15, 26, 57). To employ
this approach as a test of the coactivator function of hTAFII130 for NFATp, we constructed a partial TFIID
complex consisting of hTBP, hTAFII250, and
hTAFII130. A comparable complex,
hTBP/hTAFII250/hTAFII100, sharing all but
one component (hTAFII100 in place of hTAFII130) was constructed as a negative control. With the exception of hTBP, which was expressed in E. coli, the remaining components
were made in insect cells infected with individual baculoviruses for each recombinant protein. hTAFII250 was N-terminally tagged
with an HA epitope, and both hTAFII100 and
hTAFII130 were N-terminally FLAG tagged. The general scheme
for complex assembly and elution is depicted in Fig.
4A. Complexes were assembled in a
step-wise manner as follows. In the first phase, the
hTBP/hTAFII250 complex was preassembled on anti-HA
affinity resin by immobilizing HA-TAFII250 first and adding
recombinant TBP next, prior to the elution of the complex with an
HA-epitope peptide. At this point, the hTBP/hTAFII250 complex was analyzed by SDS-PAGE (data not shown) and tested for activity in basal and NFATp-activated transcription (Fig. 4B). As
anticipated, the hTBP/hTAFII250 complex supported basal
transcription at levels similar to holo-TFIID but did not support high
levels of NFATp transcriptional activation. In the second phase of the assembly reactions (Fig. 4A), recombinant FLAG-hTAFII130
and FLAG-hTAFII100 were immobilized on M2 beads. The
preassembled hTBP-hTAFII250 complex was added next,
allowing association with either FLAG-hTAFII130 or
FLAG-hTAFII100. The final forms of the complexes were
eluted with a FLAG-epitope peptide. Analysis of the constituents of
both complexes by SDS-PAGE and silver staining indicated that
individual subunits were incorporated at comparable levels into the
partial TFIID complexes (Fig. 4C).
|
Overexpression of hTAFII130 inhibits NFATp-activated transcription in cells. In previous studies, transient overexpression of hTAFII130 in cells had differing effects on transcriptional activation. The exogenous expression of hTAFII130 potentiated the level of activation by some activators (40) while repressing or having a dominant-negative effect on activation by other activators (38, 53). To conduct similar experiments, we constructed an NFAT-responsive reporter by introducing three NFAT sites upstream of the E1B-TATA core promoter and the firefly luciferase gene. We tested this reporter for responsiveness to overexpressed NFATp in Cos-1 cells. Transfection efficiency was monitored in all samples by cotransfection with a pRT-TK-Renilla luciferase plasmid. As expected, increasing amounts of NFATp induced firefly luciferase expression from the NFAT-dependent reporter; however, a control template lacking NFAT sites failed to respond (data not shown).
To assess the effect of hTAFII130 overexpression on NFAT-directed transcriptional activation, Cos-1 cells were cotransfected with expression plasmids for NFATp and hTAFII130. Portions of the transfected cell cultures were stimulated with ionomycin and PMA for various amounts of time (6, 12, and 24 h) or were unstimulated. Localization of NFATp is not dependent on ionomycin treatment in Cos cells (31); however, it was applied to cells to simulate the physiological conditions that may be conducive to NFAT-mediated activation. Similarly, cells were treated with PMA to activate PMA-responsive effectors that may support NFAT-mediated activation in vivo. Firefly luciferase values were normalized by Renilla luciferase values for each sample. As shown in Fig. 5A, NFATp caused a 6- to 10-fold increase in luciferase activity that did not depend on treatment with PMA and ionomycin. Expression of hTAFII130 did not affect luciferase activity in the absence of NFATp overexpression; however, expression of hTAFII130 significantly decreased NFATp-mediated luciferase activity under all conditions tested. The amount of hTAFII130 expression vector added to the transfections did not decrease the expression level of Renilla luciferase, which is driven by the thymidine kinase promoter (data not shown). Furthermore, the repressive effect of hTAFII130 overexpression on NFATp activation was overcome by increasing the amount of NFATp expression plasmid added to transfections (Fig. 5B). We conclude that overexpressed hTAFII130 acts as a dominant-negative inhibitor of NFATp-activated transcription in cells.
|
| |
DISCUSSION |
|---|
|
|
|---|
Here we present evidence supporting a mechanism by which NFATp potentiates transcriptional activation by direct interaction with hTAFII130, a component of the TFIID complex. Such targeting events by activators to their TAF coactivator partners are thought to enhance the recruitment and/or stabilization of TFIID to promoters. Our model of a mechanism of NFAT-mediated activation is strongly supported by three key results: (i) the presence of a direct and specific interaction between NFATp and hTAFII130 in vitro, (ii) the ability of hTAFII130 to serve as a coactivator for NFATp in vitro, and (iii) the observation that overexpressed hTAFII130 repressed NFATp activation in cells. This study is the first to demonstrate a mechanism of activation by any NFAT family member using a cell-free system.
The C-terminal domain of NFATp (aa 688 to 921) is both necessary and sufficient to bind hTAFII130. This region contains a glutamine-rich activation domain. Since hTAFII130 and dTAFII110 have been found to bind Gln-rich activation domains of other activators such as CREB and SP-1 (13, 22, 53, 56), Gln-rich regions of the C-terminal domain of NFATp may be important in hTAFII130-mediated recruitment of TFIID. Human NFATp exists as predominately two isoforms (B and C) that are splice variants, with differences only in the extreme tail end of these proteins (aa 908 to 921 and 908 to 925, respectively) (50). In the studies described here we used the B isoform of NFATp. It remains to be determined if the hTAFII130-dependent mode of activation characterized here is also applicable to the C isoform of NFATp. In either case, the amino acids shared in the C-terminal regions of the B and C isoforms of NFATp (aa 688 to 908) are unique to NFATp and are not found in other NFAT proteins, and hence it is possible that interaction with hTAFII130 is a unique property of NFATp. Future studies will be aimed at testing for TAF interactions with other NFAT family members.
When hTAFII130 was overexpressed in cells, we observed a dominant-negative effect on NFAT-activated transcription. This phenomenon has previously been observed for a number of viral and cellular activators in mammalian cells. Transcriptional activation by SP-1 and CREB, which can individually associate with hTAFII130 and dTAFII110 in vitro, was inhibited by overexpression of hTAFII130 in mammalian cells (53). Similarly, it has been shown that E1A binds directly to hTAFII130 in vitro and that overexpression of the hTAFII130 C-terminal domain repressed E1A-mediated transcriptional activation in cells in a dosage-dependent manner (18, 38). The authors of these studies have offered the following explanations for the dominant-negative effect of hTAFII130 overexpression that can also be applied to the NFATp system. It is possible to envision promoter-bound activators preferentially binding the more abundant overexpressed hTAFII130 instead of recruiting the entire TFIID complex. This would result in the loss of transcriptional activation. It is equally conceivable that hTAFII130 overexpression causes a diluting effect of another essential factor that functions in hTAFII130-mediated transcriptional activation by these activators. Our observations support the first explanation provided above in that the repressive effect of hTAFII130 overexpression on NFATp activation was overcome by increasing the amount of NFATp expression plasmid added to transfections.
Promoters, such as the IL-2 promoter, that are regulated by NFAT often contain multiple NFAT sites, many of which are part of composite elements to which NFAT and AP-1 bind cooperatively (51). It is likely that NFATp affects transcription at many levels in cells by targeting the TAFII130 subunit of the TFIID complex as well as non-TFIID factors. Our results suggest that if additional coactivators for NFATp exist in cells, they are factors other than the general transcription factors or the RNA polymerase II subunits, since TBP-supported transcription reactions were nonresponsive to NFATp. For example, the coactivators p300 and CBP have been found to bind NFATp (17).
Here we have shown that NFATp binds the TAFII130 subunit of human TFIID and that hTAFII130 is a coactivator for NFATp in a reconstituted transcription system. These in vitro studies provide the first biochemical analysis of mechanisms of transcriptional activation by the NFAT family of transactivators. We also found that overexpressed hTAFII130 blocked NFATp-activated transcription in cells. It seems likely that the interaction between NFATp and hTAFII130 plays a role in transcriptional activation at endogenous promoters; however, the identity of these promoters and the exact role of this interaction in the temporal and cell-type-specific expression of NFATp-responsive promoters awaits further study.
| |
ACKNOWLEDGMENTS |
|---|
We thank Tim Hoey, Naoko Tanese, Robert Tjian, and Anne Whalen for reagents and advice. J.A.G. is grateful to Robert Tjian and Tom Cech for their generous support, especially during the early stages of this work.
This research was supported by a Public Health Service grant, GM-55235, from the National Institutes of Health. J.A.G. is currently a Pew Scholar in the Biomedical Sciences and was a Special Fellow of the Leukemia Society of America during the early stages of this work. L.J.K. was supported in part by an NIH Predoctoral Training Grant, T32 GM08345, and by Beverly Sears Dean's Small Grants (University of Colorado).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Chemistry and Biochemistry, University of Colorado at Boulder, Campus Box 215, Boulder, CO 80309-0215. Phone: (303) 492-3273. Fax: (303) 492-5894. E-mail: james.goodrich{at}colorado.edu.
Present address: University of Washington School of Law, Seattle,
WA 98105-6617.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Albright, S. R., and R. Tjian. 2000. TAFs revisited: more data reveal new twists and confirm old ideas. Gene 242:1-13[CrossRef][Medline]. |
| 2. |
Beals, C. R.,
N. A. Clipstone,
S. N. Ho, and G. R. Crabtree.
1997.
Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction.
Genes Dev.
11:824-834 |
| 3. |
Beals, C. R.,
C. M. Sheridan,
C. W. Turck,
P. Gardner, and G. R. Crabtree.
1997.
Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.
Science
275:1930-1934 |
| 4. | Buratowski, S., S. Hahn, P. A. Sharp, and L. Guarente. 1988. Function of a yeast TATA element binding protein in a mammalian transcription system. Nature 334:37-42[CrossRef][Medline]. |
| 5. | Burke, T. W., P. J. Willy, A. K. Kutach, J. E. Butler, and J. T. Kadonaga. 1998. The DPE, a conserved core promoter element that is functionally analogous to the TATA box. Cold Spring Harbor Symp. Quant. Biol. 63:75-82[CrossRef][Medline]. |
| 6. | Burley, S. K., and R. G. Roeder. 1996. Biochemistry and structural biology of transcription factor IID (TFIID). Annu. Rev. Biochem. 65:769-799[CrossRef][Medline]. |
| 7. | Carey, M. F. 1995. A holistic view of the complex. Curr. Biol. 5:1003-1005[CrossRef][Medline]. |
| 8. | Chen, J.-L., L. D. Attardi, C. P. Verrijzer, K. Yokomori, and R. Tjian. 1994. Assembly of recombinant TFIID reveals differential coactivator requirements for distinct transcriptional activators. Cell 79:93-105[CrossRef][Medline]. |
| 9. | Chen, L., J. N. Glover, P. G. Hogan, A. Rao, and S. C. Harrison. 1998. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392:42-48[CrossRef][Medline]. |
| 10. |
Chow, C. W.,
M. Rincon,
J. Cavanagh,
M. Dickens, and R. J. Davis.
1997.
Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway.
Science
278:1638-1641 |
| 11. | Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697[CrossRef][Medline]. |
| 12. | Dynlacht, B. D., T. Hoey, and R. Tjian. 1991. Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell 55:563-576. |
| 13. |
Ferreri, K.,
G. Gill, and M. Montminy.
1994.
The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex.
Proc. Natl. Acad. Sci. USA
91:1210-1213 |
| 14. |
Flanagan, W. M., and G. R. Crabtree.
1992.
In vitro transcription faithfully reflecting T-cell activation requirements.
J. Biol. Chem.
267:399-406 |
| 15. |
Furukawa, T., and N. Tanese.
2000.
Assembly of partial TFIID complexes in mammalian cells reveals distinct activities associated with individual TATA box-binding protein-associated factors.
J. Biol. Chem.
275:29847-29856 |
| 16. |
Galasinski, S. K.,
T. N. Lively,
A. Grebe de Barron, and J. A. Goodrich.
2000.
Acetyl-CoA stimulates RNA polymerase II transcription and promoter binding by TFIID in the absence of histones.
Mol. Cell. Biol.
20:1923-1930 |
| 17. |
Garcia-Rodriguez, C., and A. Rao.
1998.
Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP).
J. Exp. Med.
187:2031-2036 |
| 18. | Geisberg, J. V., J. L. Chen, and R. P. Ricciardi. 1995. Subregions of the adenovirus E1A transactivation domain target multiple components of the TFIID complex. Mol. Cell. Biol. 15:6283-6290[Abstract]. |
| 19. | Goodrich, J. A., and R. Tjian. 1994. TBP-TAF complexes: selectivity factors for eukaryotic transcription. Curr. Opin. Cell Biol. 6:403-409[CrossRef][Medline]. |
| 20. | Ho, S., L. Timmerman, J. Northrop, and G. R. Crabtree. 1994. Cloning and characterization of NF-ATc and NF-ATp: the cytoplasmic components of NF-AT. Adv. Exp. Med. Biol. 365:167-173[Medline]. |
| 21. | Hoey, T., Y. L. Sun, K. Williamson, and X. Xu. 1995. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 2:461-472[CrossRef][Medline]. |
| 22. | Hoey, T., R. O. J. Weinzierl, G. Gill, J.-L. Chen, B. D. Dynlacht, and R. Tjian. 1993. Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72:247-270[CrossRef][Medline]. |
| 23. |
Jain, J.,
E. Burgeon,
T. M. Badalian,
P. G. Hogan, and A. Rao.
1995.
A similar DNA-binding motif in NFAT family proteins and the Rel homology region.
J. Biol. Chem.
270:4138-4145 |
| 24. | Jain, J., P. G. McCaffrey, Z. Miner, T. K. Kerppola, J. N. Lambert, G. L. Verdine, T. Curran, and A. Rao. 1993. The T cell transcription factor NFATp is a substrate for calcineurin and interacts with the DNA-binding domains of Fos and Jun. Nature 365:352-355[CrossRef][Medline]. |
| 25. | Kim, L. J., H. A. Ferguson, A. G. Seto, and J. A. Goodrich. 2000. Characterization of DNA binding, transcriptional activation, and regulated nuclear association of recombinant human NFATp. BMC Immunol. 1:1[CrossRef][Medline]. |
| 26. |
Klemm, R.,
J. A. Goodrich,
S. Zhou, and R. Tjian.
1995.
Molecular cloning and expression of the 32kD subunit of TFIID reveals interaction with VP16 and TFIIB that mediate transcriptional activation.
Proc. Natl. Acad. Sci. USA
92:5788-5792 |
| 27. |
Kokubo, T.,
D.-W. Gong,
S. Yamashita,
M. Horikoshi,
R. G. Roeder, and Y. Nakatani.
1993.
Drosophila 230-kD TFIID subunit, a functional homolog of the human cell cycle gene product, negatively regulates DNA binding of the TATA box-binding subunit of TFIID.
Genes Dev.
7:1033-1046 |
| 28. |
Lieberman, P. M., and A. J. Berk.
1994.
A mechanism for TAFs in transcriptional activation: activation domain enhancement of TFIID-TFIIA-promoter DNA complex formation.
Genes Dev.
8:995-1006 |
| 29. | Loh, C., J. A. Carew, J. Kim, P. G. Hogan, and A. Rao. 1996. T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1. Mol. Cell. Biol. 16:3945-3954[Abstract]. |
| 30. |
Lopez-Rodriguez, C.,
J. Aramburu,
A. S. Rakeman, and A. Rao.
1999.
NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun.
Proc. Natl. Acad. Sci. USA
96:7214-7219 |
| 31. | Luo, C., E. Burgeon, J. A. Carew, P. G. McCaffrey, T. M. Badalian, W. S. Lane, P. G. Hogan, and A. Rao. 1996. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. Mol. Cell. Biol. 16:3955-3966[Abstract]. |
| 32. |
Luo, C.,
E. Burgeon, and A. Rao.
1996.
Mechanisms of transactivation by nuclear factor of activated T cells-1.
J. Exp. Med.
184:141-147 |
| 33. |
Luo, C.,
K. T.-Y. Shaw,
A. Raghavan,
J. Aramburu,
F. Garcia-Cozar,
B. A. Perrino,
P. G. Hogan, and A. Rao.
1996.
Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import.
Proc. Natl. Acad. Sci. USA
93:8907-8912 |
| 34. | Lyakh, L., P. Ghosh, and N. R. Rice. 1997. Expression of NFAT-family proteins in normal human T cells. Mol. Cell. Biol. 17:2475-2484[Abstract]. |
| 35. | Malik, S., and R. G. Roeder. 2000. Transcriptional regulation through mediator-like coactivators in yeast and metazoan cells. Trends Biochem. Sci. 25:277-283[CrossRef][Medline]. |
| 36. | Masuda, E. S., J. Liu, R. Imamura, S.-I. Imai, K.-I. Arai, and N. Arai. 1997. Control of NFATx1 nuclear translocation by a calcineurin-regulated inhibitory domain. Mol. Cell. Biol. 17:2066-2075[Abstract]. |
| 37. | Masuda, E. S., Y. Naito, H. Tokumitsu, D. Campbell, F. Saito, C. Hannum, K. Arai, and N. Arai. 1995. NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus. Mol. Cell. Biol. 15:2697-2706[Abstract]. |
| 38. | Mazzarelli, J. M., G. Mengus, I. Davidson, and R. P. Ricciardi. 1997. The transactivation domain of adenovirus E1A interacts with the C terminus of human TAF(II)135. J. Virol. 71:7978-7983[Abstract]. |
| 39. |
McCaffrey, P. G.,
C. Luo,
T. K. Kerppola,
J. Jain,
T. M. Badalian,
A. M. Ho,
E. Burgeon,
W. S. Lane,
J. N. Lambert,
T. Curran,
G. L. Verdine,
A. Rao, and P. G. Hogan.
1993.
Isolation of the cyclosporin-sensitive T cell transcription factor NFATp.
Science.
262:750-754 |
| 40. |
Mengus, G.,
M. May,
L. Carre,
P. Chambon, and I. Davidson.
1997.
Human TAF(II) 135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells.
Genes Dev.
11:1381-1395 |
| 41. |
Miyakawa, H.,
S. K. Woo,
S. C. Dahl,
J. S. Handler, and H. M. Kwon.
1999.
Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity.
Proc. Natl. Acad. Sci. USA
96:2538-2542 |
| 42. | Molkentin, J. D., J. R. Lu, C. L. Antos, B. Markham, J. Richardson, J. Robbins, S. R. Grant, and E. N. Olson. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228[CrossRef][Medline]. |
| 43. | Northrop, J. P., S. N. Ho, L. Chen, D. J. Thomas, L. A. Timmerman, G. P. Nolan, A. Admon, and G. R. Crabtree. 1994. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369:497-502[CrossRef][Medline]. |
| 44. | Okamura, H., J. Aramburu, C. Garcia-Rodriguez, J. P. Viola, A. Raghavan, M. Tahiliani, X. Zhang, J. Qin, P. G. Hogan, and A. Rao. 2000. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol. Cell 6:539-550[CrossRef][Medline]. |
| 45. |
Orphanides, G.,
T. Lagrange, and D. Reinberg.
1996.
The general transcription factors of RNA polymerase II.
Genes Dev.
10:2657-2683 |
| 46. | Parvin, J. D., H. T. M. Timmers, and P. A. Sharp. 1992. Promoter specificity of basal transcription factors. Cell 68:1135-1144[CrossRef][Medline]. |
| 47. |
Porter, C. M.,
M. A. Havens, and N. A. Clipstone.
2000.
Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization.
J. Biol. Chem.
275:3543-3551 |
| 48. | Pugh, B. F., and R. Tjian. 1990. Mechanism of transcriptional activation by Spl: evidence for co-activators. Cell 61:1187-1197[CrossRef][Medline]. |
| 49. | Ranger, A. M., M. J. Grusby, M. R. Hodge, E. M. Gravallese, F. C. de la Brousse, T. Hoey, C. Mickanin, H. S. Baldwin, and L. H. Glimcher. 1998. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392:186-190[CrossRef][Medline]. |
| 50. | Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-747[CrossRef][Medline]. |
| 51. | Rooney, J. W., Y. L. Sun, L. H. Glimcher, and T. Hoey. 1995. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol. Cell. Biol. 15:6299-6310[Abstract]. |
| 52. | Ruppert, S., E. H. Wang, and R. Tjian. 1993. Cloning and expression of human TAFII250: a TBP-associated factor implicated in cell-cycle regulation. Nature 362:175-179[CrossRef][Medline]. |
| 53. |
Saluja, D.,
M. F. Vassallo, and N. Tanese.
1998.
Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators.
Mol. Cell. Biol.
18:5734-5743 |
| 54. |
Sauer, F.,
S. K. Hansen, and R. Tjian.
1995.
Multiple TAFIIs directing synergistic activation of transcription.
Science
270:1783-1788 |
| 55. |
Shaw, K. T.,
A. M. Ho,
A. Raghavan,
J. Kim,
J. Jain,
J. Park,
S. Sharma,
A. Rao, and P. G. Hogan.
1995.
Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells.
Proc. Natl. Acad. Sci. USA
92:11205-11209 |
| 56. |
Tanese, N.,
D. Saluja,
M. F. Vassallo,
J.-L. Chen, and A. Admon.
1996.
Molecular cloning and analysis of two subunits of the human TFIID complex: hTAFII130 and hTAFII100.
Proc. Natl. Acad. Sci. USA
93:13611-13616 |
| 57. |
Thut, C. J.,
J.-L. Chen,
R. Klemm, and R. Tjian.
1995.
p53 transcriptional activation mediated by TAFII40 and TAFII60.
Science
267:100-104 |
| 58. | Tjian, R., and T. Maniatis. 1994. Transcriptional activation: a complex puzzle with few easy pieces. Cell 77:5-8[CrossRef][Medline]. |
| 59. |
Turner, H.,
M. Gomez,
E. McKenzie,
A. Kirchem,
A. Lennard, and D. A. Cantrell.
1998.
Rac-1 regulates nuclear factor of activated T cells (NFAT) C1 nuclear translocation in response to Fc epsilon receptor type 1 stimulation of mast cells.
J. Exp. Med.
188:527-537 |
| 60. | Verrijzer, C. P., and R. Tjian. 1996. TAFs mediate transcriptional activation and promoter selectivity. Trends Biochem. Sci. 21:338-342[CrossRef][Medline]. |
| 61. |
Verrijzer, C. P.,
K. Yokomori,
J.-L. Chen, and R. Tjian.
1994.
Drosophila TAFII150: similarity to yeast gene TSM-1 and specific binding to core promoter DNA.
Science
264:933-941 |
| 62. |
Wang, W.,
J. D. Gralla, and M. Carey.
1992.
The acidic activator GAL4-AH can stimulate polymerase II transcription by promoting assembly of a closed complex requiring TFIID and TFIIA.
Genes Dev.
6:1716-1727 |
| 63. | Workman, J. L., and R. E. Kingston. 1998. Alterations of nucleosome structure as a mechanism of transcriptional regulation. Annu. Rev. Biochem. 67:545-579[CrossRef][Medline]. |
| 64. |
Yokomori, K.,
J.-L. Chen,
A. Admon,
S. Zhou, and R. Tjian.
1993.
Molecular cloning and characterization of dTAFII30 and dTAFII30 : two small subunits of Drosophila TFIID.
Genes Dev.
7:2587-2597 |
| 65. | Zhu, J., F. Shibasaki, R. Price, J.-C. Guillemot, T. Yano, V. Dotsch, G. Wagner, P. Ferrara, and F. McKeon. 1998. Intramolecular masking of nuclear import signal on NFAT4 by casein kinase I and MEKK1. Cell 93:851-861[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»